Review article

the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients

Mangel, AW., & Northcutt, AR. (1999). Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients. Alimentary Pharmacology and Therapeutics, 13(Suppl 2), 77-82.

Abstract

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal-related conditions. In this review, the safety and efficacy of alosetron, a potent and selective 5-HT3 receptor antagonist, in the treatment of IBS are discussed. Alosetron has been shown to produce statistically significant improvements in abdominal pain, stool consistency, stool frequency and urgency in female IBS patients. By contrast, no consistent improvement has been seen in male IBS patients treated with alosetron. The only adverse event of note with alosetron was constipation, and this represents a class effect of 5-HT3 receptor antagonists. In conclusion, alosetron is a safe and effective treatment for female IBS patients

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Long-term effects of a diet supplement containing Cannabis sativa oil and Boswellia serrata in dogs with osteoarthritis following physiotherapy treatments
Article

Use of a web-based portal to return normal individual research results in Early Check
Article

The importance of quality data to track global progress in addressing stillbirths and neonatal mortality